Aptose Biosciences (APS.TO) on Thursday announced the publication of preclinical data for its lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR).
The paper is the first preclinical profiling of tuspetinib, a once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML).
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib with two other medications. Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or with one other medication have been completed.
"The non-clinical findings presented in the publication suggest that TUS will demonstrate favorable safety and a breadth of antileukemic activity across AML patient populations with a diversity of adverse mutations, and the initial clinical data is bearing that out," said CEO William Rice.
The company's shares were last seen up $0.01 to $0.27 on the Toronto Stock Exchange.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。